#BEGIN_DRUGCARD DB01650

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
614-60-8

# ChEBI_ID:
18125

# Chemical_Formula:
C9H8O3

# Chemical_IUPAC_Name:
(2E)-3-(2-hydroxyphenyl)prop-2-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
trans-2-hydroxycinnamic acid

# HET_ID:
2HC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H8O3/c10-8-4-2-1-3-7(8)5-6-9(11)12/h1-6,10H,(H,11,12)/b6-5+

# InChI_Key:
InChIKey=PMOWTIHVNWZYFI-AATRIKPKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C01772

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1650

# Mechanism_Of_Action:
Not Available

# Melting_Point:
217 dec Â°C

# Molecular_Weight_Avg:
164.158

# Molecular_Weight_Mono:
164.047344122

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1V5Z

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.9

# Predicted_LogS:
-2.1

# Predicted_Water_Solubility:
1.15e+00 g/l

# Primary_Accession_No:
DB01650

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
637540

# PubChem_Substance_ID:
46505688

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00123

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)\C=C\C1=CC=CC=C1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(2E)-3-(2-HYDROXYPHENYL)ACRYLIC ACID
(2E)-3-(2-Hydroxyphenyl)-2-propenoic acid
(2E)-3-(2-hydroxyphenyl)prop-2-enoic acid
(E)-3-(2-Hydroxyphenyl)-2-propenoic acid
(e)-o-hydroxycinnamic acid
2-Coumarate
2-Coumaric acid
2-Hydroxycinnamate
2-Hydroxycinnamic acid
3-(2-hydroxyphenyl)acrylic acid
3-(2-hydroxyphenyl)prop-2-enoic acid
O-Coumaric Acid
O-hydroxy-trans-cinnamic acid
O-hydroxycinnamic acid
Ortho-hydroxycinnamic acid
Trans-o-coumaric acid
Trans-o-hydroxycinnamic acid
trans-2-Hydroxycinnamate

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:21 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D17743

# Drug_Target_1_GenBank_ID_Protein:
6539550

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>657 bp
ATGACGCATCCAATTATTCATGATCTTGAAAATCGTTATACATCAAAAAAATATGACCCA
TCAAAGAAAGTATCTCAAGAAGATTTAGCGGTTTTGCTTGAGGCTCTGCGTTTATCTGCT
TCTTCAATTAATTCACAGCCTTGGAAATTCATTGTTATTGAATCCGATGCAGCGAAGCAA
CGTATGCATGATTCGTTTGCAAATATGCATCAGTTTAATCAACCTCACATCAAAGCGTGT
TCTCATGTGATTTTATTTGCAAATAAGCTTTCGTATACACGAGATGATTATGATGTGGTT
TTATCTAAAGCGGTTGCTGACAAGCGTATTACTGAAGAGCAAAAAGAAGCTGCTTTTGCT
TCGTTTAAGTTTGTAGAATTGAACTGTGATGAAAATGGTGAGCATAAAGCATGGACTAAG
CCTCAAGCTTATTTAGCTCTTGGTAATGCTCTGCATACATTAGCTAGACTGAACATTGAC
TCAACAACAATGGAAGGCATTGATCCTGAATTATTGAGTGAAATTTTTGCTGATGAATTA
AAAGGGTATGAATGTCATGTTGCTTTAGCCATTGGTTATCATCATCCAAGCGAAGATTAT
AATGCCTCTTTGCCTAAGTCTCGTAAGGCATTTGAAGACGTAATTACCATCCTTTAG

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
8033996	Inouye S: NAD(P)H-flavin oxidoreductase from the bioluminescent bacterium, Vibrio fischeri ATCC 7744, is a flavoprotein. FEBS Lett. 1994 Jun 27;347(2-3):163-8.
8206830	Zenno S, Saigo K, Kanoh H, Inouye S: Identification of the gene encoding the major NAD(P)H-flavin oxidoreductase of the bioluminescent bacterium Vibrio fischeri ATCC 7744. J Bacteriol. 1994 Jun;176(12):3536-43.
9654450	Koike H, Sasaki H, Kobori T, Zenno S, Saigo K, Murphy ME, Adman ET, Tanokura M: 1.8 A crystal structure of the major NAD(P)H:FMN oxidoreductase of a bioluminescent bacterium, Vibrio fischeri: overall structure, cofactor and substrate-analog binding, and comparison with related flavoproteins. J Mol Biol. 1998 Jul 10;280(2):259-73.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2261

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
24721

# Drug_Target_1_Name:
Major NAD(P)H-flavin oxidoreductase

# Drug_Target_1_Number_of_Residues:
218

# Drug_Target_1_PDB_ID:
1VFR

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_1_Protein_Sequence:
>Major NAD(P)H-flavin oxidoreductase
MTHPIIHDLENRYTSKKYDPSKKVSQEDLAVLLEALRLSASSINSQPWKFIVIESDAAKQ
RMHDSFANMHQFNQPHIKACSHVILFANKLSYTRDDYDVVLSKAVADKRITEEQKEAAFA
SFKFVELNCDENGEHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDPELLSEIFADEL
KGYECHVALAIGYHHPSEDYNASLPKSRKAFEDVITIL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in bioluminescence. It is a good supplier of reduced flavin mononucleotide (FMNH2) to the bioluminescence reaction. Major FMN reductase. It is capable of using both NADH and NADPH as electron donors. As electron acceptor, FMN is the most effective, FAD is considerably effective, and riboflavin is the least effective

# Drug_Target_1_SwissProt_ID:
P46072

# Drug_Target_1_SwissProt_Name:
FRA1_VIBFI

# Drug_Target_1_Synonyms:
EC 1.6.99.-
FRASE I

# Drug_Target_1_Theoretical_pI:
6.12

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01650
